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Résumé de la thèse: Does this patient have Acute Mountain Sickness? The Rational Clinical 
Examination Systematic Review. JAMA November 14, 2017. 
Importance du sujet 
Le mal aigu des montagnes (en anglais : Acute Mountain Sickness, ou AMS) est une pathologie 
fréquente, touchant >25% des individus atteignant une altitude de 3500m et >50% de ceux arrivant 
au-delà de 6000m. L’AMS est caractérisé par des symptômes peu spécifiques, et habituellement 
bénins, mais, qui, dans <1% des cas, peuvent évoluer vers l’œdème cérébral d’altitude, pathologie 
pouvant engager le pronostic vital. Le meilleur moyen de diagnostiquer l’AMS est encore peu clair. 
Objectif 
Effectuer une revue systématique des études s’intéressant aux instruments diagnostic de l’AMS et 
comparer les performances (rapports de vraisemblance (LR+ et LR-), sensibilité et spécificité) de ces 
différents instruments. 
Extraction des données et synthèse 
Les bases de données MEDLINE et EMBASE ont été analysées, depuis leur création, jusqu’à mai 
2017, avec mise en évidence de 1245 publications : 91 contenant des données de prévalence de l’AMS 
(66,944 participants) et 14 comparant ≥2 instruments (1858 participants), et ayant le Lake Louise 
Questionnaire Score ≥5 (LLQS≥5) comme standard de référence. 
Résultats 
Sept instruments différents pour le diagnostic de l’AMS ont été identifiés par la recherche de 
littérature : Le Lake Louise Questionnaire score(LLQS), l’AMS-Cerebral score (AMS-C), l’échelle 
visuelle analogue globale et composite (VAS[O], et VAS[C]), le Hackett clinical score, le Chinese 
AMS score, et le Clinical Functional Score (CFS). Une analyse comparative des performances n’a pu 
être réalisée que pour 4 de ces scores (LLQS, AMS-C, VAS[O], et CFS). 
Pour tous ces instruments, l’altitude est un prédicteur de l’AMS et est responsable de 28% de 
l’hétérogénéité entre les études. Pour chaque tranche de 1000m d’altitude gagnés au-dessus de 
2500m, la prévalence de l’AMS augmente de 13% (intervalle de confiance 95% [CI] 9.5-17%). 
Comparés au LLQS≥5, le VAS(O), le AMS-C≥0.7), et le CFS≥2, ont des performances similaires 
(un rapport de vraisemblance positif (LR+) entre 3.2 à 8.2; p=0.22) avec une spécificité allant de 67 
à 92% ; rapports de vraisemblance négatifs (LR-) entre 0.30 à 0.36, p=0.50), avec une sensibilité de 
67 à 82%). Le CFS est composé d’une question unique : “ De façon globale, si vous souffrez de 
symptômes, de quelle manière ont-ils affecté votre activité (échelle de 0-3) ?” Pour une réduction 
modérée à sévère des activités quotidiennes (CFS≥2), le LR+ est de 3.2 (CI 1.4-7.2), et la spécificité 
de 67 % (CI 37-97) ; en cas d’absence de réduction ou d’une réduction légère (CFS<2), le LR- est de 
0.30 (CI 0.22-0.39) et la sensibilité de 82% (CI 77-87). 
Conclusions  
Malgré le nombre important de publications concernant l’AMS, il n’y a que peu d’études qui ont 
comparé les performances des différents instruments diagnostics de l’AMS entre-elles, et la qualité 
de ces données est critiquable. Les différents scores analysables (VAS(O), AMS-C et CFS), semblent 
avoir des performances similaires au LLQS≥5. Le CFS est l’instrument le plus simple à utiliser. Les 
cliniciens s’occupant de voyageurs en altitude rapportant une réduction modérée à sévère de leur 
activité quotidienne en lien avec les symptômes d’AMS (CFS≥2) devraient utiliser le LLQS pour 
mieux caractériser la sévérité de l’AMS. 
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Does This Patient Have AcuteMountain Sickness?
The Rational Clinical Examination Systematic Review
David Meier, MD; Tinh-Hai Collet, MD; Isabella Locatelli, PhD; Jacques Cornuz, MD, MPH;
Bengt Kayser, MD, PhD; David L. Simel, MD, MHS; Claudio Sartori, MD
IMPORTANCE Acute mountain sickness (AMS) affects more than 25% of individuals ascending
to 3500m (11 500 ft) andmore than 50% of those above 6000m (19 700 ft). AMSmay
progress from nonspecific symptoms to life-threatening high-altitude cerebral edema in less
than 1% of patients. It is not clear how to best diagnose AMS.
OBJECTIVE To systematically review studies assessing the accuracy of AMS diagnostic
instruments, including the visual analog scale (VAS) score, which quantifies the overall feeling
of sickness at altitude (VAS[O]; various thresholds), Acute Mountain Sickness-Cerebral score
(AMS-C;0.7 indicates AMS), and the clinical functional score (CFS;2 indicates AMS)
compared with the Lake Louise Questionnaire Score (LLQS; score of5).
DATA EXTRACTION AND SYNTHESIS Searches ofMEDLINE and EMBASE from inception
to May 2017 identified 1245 publications of which 91 were suitable for prevalence analysis
(66 944 participants) and 14 compared at least 2 instruments (1858 participants) using
a score of 5 or greater on the LLQS as a reference standard. To determine the prevalence
of AMS for establishing the pretest probability of AMS, a random-effects meta-regression
was performed based on the reported prevalence of AMS as a function of altitude.
MAIN OUTCOMES ANDMEASURES AMS prevalence, likelihood ratios (LRs), sensitivity,
and specificity of screening instruments.
RESULTS The final analysis included 91 articles (comprising 66944 study participants).
Altitude predicted AMS and accounted for 28% of heterogeneity between studies. For each
1000-m (3300-ft) increase in altitude above 2500m (8200 ft), AMS prevalence increased
13% (95% CI, 9.5%-17%). Testing characteristics were similar for VAS(O), AMS-C, and CFS
vs a score of 5 or greater on the LLQS (positive LRs: range, 3.2-8.2; P = .22 for comparisons;
specificity range, 67%-92%; negative LRs: range, 0.30-0.36; P = .50 for comparisons;
sensitivity range, 67%-82%). The CFS asks a single question: “overall if you had any
symptoms, how did they affect your activity (ordinal scale 0-3)?” For CFS, moderate to severe
reduction in daily activities had a positive LR of 3.2 (95% CI, 1.4-7.2) and specificity of 67%
(95% CI, 37%-97%); no reduction tomild reduction in activities had a negative LR of 0.30
(95% CI, 0.22-0.39) and sensitivity of 82% (95% CI, 77%-87%).
CONCLUSIONS AND RELEVANCE The prevalence of acutemountain sickness increases with
higher altitudes. The visual analog scale for the overall feeling of sickness at altitude, Acute
Mountain Sickness-Cerebral, and clinical functional score perform similarly to the Lake Louise
Questionnaire Score using a score of 5 or greater as a reference standard. In clinical and travel
settings, the clinical functional score is the simplest instrument to use. Clinicians evaluating
high-altitude travelers who report moderate to severe limitations in activities of daily living
(clinical functional score2) should use the Lake Louise Questionnaire Score to assess the
severity of acute mountain sickness.
JAMA. 2017;318(18):1810-1819. doi:10.1001/jama.2017.16192
JAMA Patient Page page 1840
Supplemental content
CMEQuiz at
jamanetwork.com/learning
and CMEQuestions page 1824
Author Affiliations:Author
affiliations are listed at the end of this
article.
Corresponding Author: Tinh-Hai
Collet, MD, Service of Endocrinology,
Diabetes, andMetabolism, Lausanne
University Hospital, Bugnon 46,
1011 Lausanne, Switzerland
(tinh-hai.collet@chuv.ch).
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Clinical Scenario
A52-year-oldhealthyman livingatsea levelarrivesatahotelat4000
m(13 100 ft) after traveling all day. This is his first exposure to an al-
titude above 2500m (8200 ft). When walking to dinner that eve-
ning he feels unusually exhausted, has shortness of breath anddiz-
ziness, andexperiencespalpitations andnausea.He is unable toeat
andmust return to his room.Which diagnostic instruments can be
used todetermine if these symptomsare indicativeof severe acute
mountain sickness (AMS)?
Traveling to high altitude for recreational purposes has become in-
creasingly popular but risks the development of AMS. AMS affects
more than 25% of individuals ascending to 3500 m (11 500 ft)
and more than 50% of those reaching elevations above 6000 m
(19 700 ft).1-3 AMS affects
otherwise healthy persons,
develops within hours after
arriving at altitude, and re-
sults in functional impair-
ment from symptoms that
may include headache,
anorexia, nausea, vomiting,
dizziness, fatigue, and sleep
disturbances.4 In the vast
majority of cases, these symptoms resolve spontaneously after 18
to 36 hours without requiring (curative) descent to lower altitude,
but in fewer than 1% of individuals with AMS, the disease pro-
gresses to life-threatening high-altitude cerebral edema mani-
fested by an altered level of consciousness and ataxia.
ThepathophysiologyofAMSandhigh-altitude cerebral edema
is not fully understood. Exaggerated cerebral vasodilation, in-
creased sympathetic activity, diminishedhypoxic ventilatorydrive,
severe hypoxemia (especially during sleep), increased salt andwa-
ter retention,and increasedoxidativestressand inflammationallmay
contribute to the development of AMS.4-7
Identified risk factors for AMS can be grouped in the follow-
ing ways: (1) an individual’s health, physiology, and genetics; and
(2) specific behaviors and activities performed at high altitude.
Although a recent meta-analysis challenged this concept,8 the
most widely recognized risk factor is an individual person’s suscep-
tibility to AMS. After a first episode of AMS, the risk of recurrence
following reascent in similar conditions (rapidity of ascent, absolute
altitude, no medical prophylaxis) can be as high as 60% with
an odds ratio (OR) of as much as 12. Estimates of this risk vary
by the type of diagnostic instrument used to establish a diagnosis
of AMS.9-15 Although not yet demonstrated in humans, animal
studies suggest that individual susceptibility to AMS can be
explained by genetic differences in the respiratory drive.16-18 The
risk for AMS is as much as 2.06-fold (95% CI, 1.15-3.72) lower for
people older than 50 years.12,14,19-22 Women may be more likely
affected than men,19,22,23 but this finding is not consistent.11,13,14,24
Medical conditions such as migraine,10,11,25 obesity,22,26 and mood
states (anxiety) might also play a role in the development of AMS,27
whereas smoking and alcohol consumption do not appear to
increase the risk for AMS.3,20,28
The most important modifiable behaviors at altitude that can
influence the risk of developing AMS are the altitude attained and
speedof ascent.9,11,15,20Ascents that are faster than400mperday
(1300 ft/d) haveanORof4.69 (95%CI, 2.79-7.90),whereas slower
ascents have an OR of 0.30 (95% CI, 0.20-0.44) for the develop-
mentofAMS.AMS is less likely todevelopwhen therehasbeenpre-
acclimatization (ie, previous exposure to altitude within 1-2
months)9,14,19,20 or medical prophylaxis with acetazolamide or
dexamethasone.29-31 In contrast, physical training does not reduce
the risk for developing AMS.11,12,15,20,26,32
There are no biomedical tests that can establish a diagno-
sis of AMS; consequently, the diagnosis is made from clinical fea-
tures. AMS is characterized by subjective symptoms (headache,
anorexia, nausea, sometimesvomiting,dizziness, fatigue, andsleep
disturbances) and, less frequently, few objective clinical signs
(ataxia, palpitations, pulmonary rales, cyanosis) reportedby the af-
fected individual or through observationsmade by travel compan-
ions of personswith AMS.16 The presence and intensity of these al-
titude-related symptoms, their associated functional impairment,
or both are assessed using a variety of diagnostic instruments.
TheAcuteMountain Sickness-Cerebral score (AMS-C), theHackett
clinical score, and the Lake Louise Questionnaire Score (LLQS)
are the instruments used most frequently to establish a diagnosis
ofAMS.Eachof these instrumentswasderived fromapreviousnon-
altitude-specific Environmental Symptoms Questionnaire III score
and are calculated as the sum of values given to different symp-
toms and signs weighted by their severity. Different cutoff values
have been used to establish a diagnosis of AMS using the LLQS.
In general, values larger than 5 points have been considered diag-
nostic of moderate to severe AMS. The Chinese AMS score, also
based on the presence of several symptoms, is almost exclusively
used inChina.Avisual analog scale (VAS) score,quantifying thesub-
jective feeling of overall severity of sickness at altitude (VAS[O]), is
themost recent instrument to be used for diagnosing AMS and has
no commonly accepted cutoff value. The clinical functional score
(CFS) is the simplest instrument to use because it relies on a single
question: “Overall if youhadanysymptoms,howdid theyaffectyour
daily activity?” scoredonanordinal scale of0 to3 (Table 1 andeAp-
pendix 1 in the Supplement). Despite several of these instruments
AMS acute mountain sickness
AMS-C AMS-Cerebral score
CFS clinical functional score
LLQS Lake Louise Questionnaire
Score
VAS visual analog scale
VAS(O) VAS for the overall feeling
of mountain sickness
Key Points
Question What is the best instrument to use for diagnosing acute
mountain sickness (AMS)?
Findings In a systematic review of studies assessing the accuracy
of existing AMS diagnostic instruments, the visual analog scale for
the overall feeling of sickness at altitude (VAS[O]) score, the Acute
Mountain Sickness-Cerebral score (AMS-C), and the clinical
functional score (CFS) had similar testing characteristics for
diagnosing AMS as did a reference standard (the Lake Louise
Questionnaire Score [LLQS] using5 to indicate a positive test
result).
Meaning Although these instruments emphasize different clinical
features, they all performed similarly for establishing a diagnosis of
AMS. The clinical functional score is the simplest instrument to use
for diagnosing AMS because it relies on a single question and
emphasizes functional limitations resulting from AMS.
Does This Patient Have AcuteMountain Sickness? The Rational Clinical Examination Clinical Review& Education
jama.com (Reprinted) JAMA November 14, 2017 Volume 318, Number 18 1811
© 2017 American Medical Association. All rights reserved.
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having been extensively used in clinical and research settings, how
theyperform relative tooneanother hasnot been studied indetail.
Wecompared the relativeperformanceof the instrumentsused
to diagnoseAMSagainstwhat is commonly considered a reference
standard, theLLQS,using itshighest thresholdof5pointsorgreater
toestablishadiagnosisof severeAMS,which isassociatedtoahigher
risk of developing life-threatening high-altitude cerebral edema.24
Becauseuseof adiagnostic test requires knowing thepretest prob-
abilityof adiseasebeingpresent,we reviewed the literature regard-
ing the presence of AMS as a function of altitude.
Methods
Literature Search Strategy
ThePRISMAStatementwas followed to systematically reviewpub-
lished literature on AMS (eFigure in the Supplement). MEDLINE
and EMBASEwere searched from inception toMay 22, 2017, with-
out languagerestriction to identifyAMS inunselectedvisitors tohigh
altitude. Keywords from the Rational Clinical Examination search
strategy38 were combined with the MeSH keywords acute moun-
tain sickness and altitude sickness (eAppendix 2 in the Supple-
ment). Additional relevant articles were identified from searching
the bibliographies of retrieved articles. Original studies that re-
portedepidemiologicaldata,describeddiagnosticprocedures,or in-
cluded comparison of different diagnostic instruments (including
both observational and intervention study designs)were included.
Review articles, studies that lacked clinical data, those inwhich the
diagnostic procedurewasnot clearly defined, and thosedealingex-
clusively with children or adolescents were excluded. High-
altitudepulmonaryedema (a separateentity fromAMSthathasdif-
ferent pathophysiological mechanisms) was not reviewed.39
Each abstract was reviewed independently by 2 authors (D.M. and
T.-H.C.) to ensure that relevant publications met inclusion criteria.
Subsequently, these same investigators independently reviewed
each full-text article to confirm that inclusion and exclusion criteria
were met and also abstracted data from the included studies.
Disagreementswere resolved by discussion, and, when necessary,
consensus was reached with a third author (C.S.).
Data Extraction From Selected Articles and Quality Ratings
Fromeach selected article, data on the prevalence of AMS, altitude
above sea level, and the diagnostic instrument(s) used were ex-
tracted. If necessary, additional data were obtained by contacting
the authors of the original studies.
For eligible studies, the risk of bias and applicability concerns
were evaluated using the Quality Assessment of Diagnostic Accu-
racyStudies2(QUADAS-2)criteria40by2coauthors(D.M.andT.-H.C.).
TheitemsordomainsinQUADAS-2werelabeledasunknownifthecor-
responding study characteristicswere not reported. Disagreements
inqualityassessmentwere resolvedbyconsensusamongcoauthors.
Choice of Reference Standard
To compare different instruments, the LLQSwas selected as the ref-
erence instrumentbasedonexpertopinionandbecausetheLLQShas
become themost frequently studied comparator scale. Expert opin-
ion is that a threshold score of 3 or greater enhances the opportunity
todetectmildAMSbutmayresult inoverdiagnosis.Moststudiesevalu-
ated the LLQS at various cutoffs. For the present review, the highest
cutoff (a score of5)was used as the reference standard.24
Statistical Analyses
TodeterminetheprevalenceofAMSforestablishingthepretestprob-
ability of AMS, a random-effects meta-regression was performed
basedonthereportedprevalenceofAMSasafunctionofaltitude.The
midpointof the rangeofaltitudes reportedbystudyparticipantswas
used to assign an altitude for each study included in this analysis.
Apooledanalysiswasperformedthat includedall thedata, thenscore-
specific meta-regressions were performed to compare the relation-
ship between theprevalence ofAMSand altitude for the LLQSusing
various thresholds for establishing the presence of AMS (LLQS3,
LLQS4, and LLQS5): the AMS-C of 0.7 or greater (derived from
the Environmental Symptoms Questionnaire III, see eAppendix 1 in
the Supplement); the Hackett clinical score of 3 or greater; and the
Chinese AMS score. In studies using the VAS(O) for AMS, differing
thresholds (as defined in each article) were used to establish a diag-
nosis of AMS. Between-study variance was estimated using the
I2 statistic.41 Theproportionofbetween-studyvarianceexplainedby
altitudewas estimated using the R2 statistic.
The3 instruments that couldbe comparedwith theLLQSwere
theAMS-C, theVAS(O), and the CFS. To obtain summary estimates
of likelihoodratio(LR),sensitivity,andspecificitywithrespective95%
CIs for each of the 3 instruments, a bivariable analysis for findings
derived from more than 4 studies was used, and a univariable ap-
proachwas used for studies inwhich therewere fewer than 3 stud-
ies because of sparse data and lack of model convergence.42
Analyses were performed using the packagesmeta andmeta-
for in the R software package (R Foundation), version 3.2.2; Stata
(StataCorp), version 14.2; SAS (SAS Institute), version9.2; andCom-
prehensive Meta-Analysis (BioStat), version 2.2.064.
Results
The search yielded 1245 citations in the MEDLINE and EMBASE
databases and 34 additional citations throughmanual screening of
references (eFigure in the Supplement). After screening titles and
abstracts, 838 abstracts were excluded (eFigure in the Supple-
ment),and407full-textarticleswereassessedforeligibility (ofwhich
305 were excluded because they focused on altitude-related dis-
easeother thanAMSorbecausealtitudedata, thediagnostic instru-
ment, or cutoff value usedwere not reported). Among the remain-
ing 102 articles, 7 were excluded from the summary measures
including 1 study that was limited to children aged 4 to 11 years at
1605m(5300ft)of altitude43andastudyof teenagershikingat low
altitudesbutnot associatedwithmountain sickness.44The final se-
lection comprised 91 articles (66 944 participants) for AMS preva-
lence (eTable 2 in the Supplement) using 6 different instruments:
theAMS-C,Hackett clinical score, theLLQS, theChineseAMSscore,
the VAS(O), and the CFS.
Prevalence of AcuteMountain Sickness
Random-effects meta-regression showed that studies conducted
at higher altitudes reported a higher prevalence of AMS. Above
2500 m (8200 ft), for every 1000-m increase (3300-ft increase)
in altitude, there was a 13% increase (95% CI, 9.5%-17%) in the
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prevalence of AMS (Figure; Table 2). The majority of data was
obtained from studies using the LLQS with a cutoff score of at
least 3 to diagnose AMS. Despite the narrow CI, there was sig-
nificant heterogeneity (I2 = 98%) among these studies. The
heterogeneity was partly explained (28%) by different altitudes
examined in the studies. The contributions from other known
determinants of AMS (such as speed of ascent, preacclimatiza-
tion, and prophylaxis) could not be established because of insuffi-
cient detailed data on these factors.
Performance of AcuteMountain Sickness
Diagnostic Instruments
Fourteen of the studies included head-to-head comparisons be-
tween at least 2 different AMS diagnostic instruments (1858
participants),22,45-47,52-61 of which only 8 facilitated head-to-head
comparative analysis used the LLQS score of 5 or greater as the ref-
erence standard (1344participants)22,45-47,52-55 (Table3). Basedon
theQUADAS-2 tool assessing thequalityof studiesondiagnostic ac-
curacy included in systematic reviews, these8studieshada lowrisk
of bias and fewapplicability concerns (eTable 1 in the Supplement);
therefore, they were used to pool summary estimates (Table 4).
Using an LLQS score of 5 or greater as the reference standard
for establishing a diagnosis of AMS (Table 4), summary measures
wereas follows: for theVAS(O) (various thresholds):positiveLR,7.6;
negative LR, 0.35; sensitivity, 69%; and specificity, 91%; for the
AMS-C (scoreof0.7 indicatesAMS): positiveLR,8.2; negativeLR,
0.36; sensitivity,67%;andspecificity,92%; for theCFS (scoreof2
indicatesAMS):positiveLR,3.2;negativeLR,0.30; sensitivity,82%;
and specificity, 67%.Whencomparing theseperformances, no sta-
tistical differences were found for the comparison of positive LRs
Table 2. The Effect ofMean Altitude on Prevalence of AcuteMountain Sickness for Various Diagnostic Instruments, Assessed by Random-Effects
Meta-Regressiona
AMS Diagnosis Level No. of Studiesb No. of Participants
Increase in AMS Prevalence
per 1000 m, % (95% CI) P Value I2, % R2, %
AMS-C ≥0.7 13 3206 13.3 (0.5 to 26.0) .04 97 26
Hackett clinical score ≥3 6 4690 18.3 (10.9 to 25.6) <.001 88 71
LLQS
≥3 62 36 531 13.8 (7.4 to 20.2) <.001 97 24
≥4 11 7551 7.7 (1.5 to 13.9) .015 94 36
≥5 14 3186 17.8 (9.2 to 26.3) <.001 93 58
Chinese AMS score 4 11 780 15.1 (−3.6 to 33.7) .11 99 17
Pooled 110c 66 944 13 (9.5 to 17) <.001 98 28
Abbreviations: AMS, acute mountain sickness; AMS-C, AMS-Cerebral score;
LLQS, Lake Louise Questionnaire Score.
Conversion factor: To convert meters to feet, divide by 0.3048.
a Based on the random-effects meta-regressionmodel of the 6 scores in 91
studies, the predicted prevalence (%) ≈ 13.4 × [altitude (m)/1000] − 21.5.
For example, travelers at 2500mwould have an estimated prevalence
of 12% ≈ 13.4 × [2500/1000] − 21.5.
b The number of studies was too low for meaningful meta-regression of the
Hackett clinical score with a different cutoff (2; 4 studies34,48-50),
the visual analog scale score (4 studies with only 2 allowing prevalence
analysis45,46), the clinical functional score (2 studies22,47), and the LLQS
(7 points; 1 study51).
c Some studies reportedmore than 1 instrument at a given altitude, explaining
why the total number of studies for pooled analyses is greater than the
number of included studies (91).
Figure. Random-EffectsMeta-Regression of Prevalence of AcuteMountain Sickness According to Altitude
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(χ22 = 3.0;P = .22) and for the comparisonofnegativeLRs (χ
2
2 = 1.4;
P = .50). Among these 3 instruments, the heterogeneity was high-
est for the positive LR of the CFS, attributable to the study by
Maggiorini et al,47which included thehighest number of studypar-
ticipants (n = 490) and had a positive LR of 11, sensitivity of 77%,
and specificity of 93% (Table 4).
Discussion
Sevendifferent instruments (LLQS,AMS-C,VAS[O],VAS[C],Hackett
clinical score, ChineseAMSscore, andCFS)were found in the litera-
ture in which the diagnosis of AMS was described. For 5 of these
Table 3. Major Characteristics of Publications Including Head-to-Head Comparisons Between AcuteMountain Sickness Diagnostic Instruments
Source
(Location)
No. of Participants/
No. of Measurements
Women,
%
Mean
Age, y
BMI,
Mean Altitude, m
History
of AMS
Prior
Acclimatization
Speed
of Ascent
Prophylaxis
Allowed
Test
Evaluated
Reference
Standard
Comparative Analysis With the Reference Standard of LLQS ≥5a
Maggiorini
et al,47 1998
(Swiss Alps)b
Mountaineers,
490/490
19 37 20 2850-4559 NS Partial 1-d
ascent
NS LLQS ≥4,
LLQS ≥5,
Hackett ≥3,
AMS-C
LLQS ≥5
Dellasanta
et al,52 2007
(Nepal)c,d
Trekkers,
266/1033
42 37 NS 3500-5400 NS NS 2-5 d Yes CFS LLQS ≥3,
LLQS ≥4,
LLQS ≥5,
AMS-C ≥0.7
Kayser et al,53
2010
(Swiss Alps)c,d
Trekkers,
14/80
0 42 25 3647-4560 NS No >3 d No VAS(O),
AMS-C
LLQS ≥3,
LLQS ≥5
Van Roo,
et al,54 2011
(Acacongua,
Argentina)e
Mountaineers,
66/45
9.9 42 24.5 4365-6962 NS NS 389m/d Yes VAS(O) LLQS ≥5
Wagner
et al,45 2012
(Orizaba,
Mexico)
Mountaineers,
63/63
12 34 NS 4260-5640 NS NS >2 d NS VAS(O) LLQS ≥5,
AMS-C ≥0.7
Dehnert et al,55
2014
(Germany)e,f
Volunteers,
76/73
0 26.5 23.6 569-4500 NS No NS
(simulated)
No AMS-C LLQS ≥3,
LLQS ≥4,
LLQS ≥5
McDevitt
et al,22
2014 (Nepal)c
Trekkers,
337/337
51 35 23 2670-5400 NS NS >4 d Yes, 44%
using
acetazolamide
CFS LLQS ≥3,
LLQS ≥5
Frühauf et al,46
2016
(Swiss Alps)
Volunteers,
32/32
60 38.8 22.7 3650 All Partial 1-d ascent NS VAS LLQS ≥5
Comparative Analysis Without the Reference Standard of LLQS ≥5f
Savourey
et al,56 1995
(France)c,d,g
Soldiers,
9/9
0 33 22.5 4500-5500 NS None 9 h
(simulated)g
Yes LLQS ≥3 AMS-C ≥0.7,
Hackett ≥3
Roeggla
et al,57 1996
(Austria)
Mountaineers,
99/99
29 35.4 NS 2940 None NS 1-d
ascent
No LLQS ≥3 Hackett ≥3
Hext et al,58
2011
(Chili)d
Volunteers,
23/138
26 42 NS 4392 NS No >3 d NS VAS(O) LLQS ≥3,
AMS-C ≥0.7
Slingo et al,59
2012
(Ladakh, India)
Volunteers,
28/1288
21 21 NS 3500-6000 NS Yes NS NS VAS(O) LLQS ≥3,
LLQS ≥5
Chen et al,60
2013
(China)
Soldiers,
339/339
1 1 22.4 3200 NS No >2 d NS Chinese AMS LLQS ≥3
Subudhi
et al,61 2014
(Chacaltaya,
Bolivia)
Volunteers,
21/21
43 43 22.4 5260 NS No 3 h
(from 4000 m)
No AMS-C LLQS ≥3
Abbreviations: AMS-C, Acute Mountain Sickness-Cerebral score; BMI, body
mass index (calculated as weight in kilograms divided by height in meters
squared); CFS, clinical functional score; LLQS, Lake Louise Questionnaire Score;
NS, not specified; VAS(O), visual analog scale for the overall feeling of
mountain sickness.
Conversion factor: To convert meters to feet, divide by 0.3048.
a These studies were used for the comparative analysis with the reference
standard of LLQS5 in Table 4.
b In the original study, the CFS was used as the reference standard. Because of
detailed tables available in the publication, sensitivity-specificity 2 × 2 tables
were able to be recalculated the using the LLQS5 as the reference standard
for the purpose of this analysis.
c Additional data were obtained from the authors and used for the calculations.
d The number of participants is less than the number of samples because of
measurement of the same participants at multiple altitudes.
e The number of participants is greater than the number of samples because of
incomplete data for some participants.
f These studies could not be included in the comparative analysis with LLQS5
in Table 4 because of insufficient data to reconstruct the sensitivity-specificity
2 × 2 tables.
g Simulated ascent was performed in hypobaric or normobaric hypoxia
laboratory conditions.
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instruments(LLQS,AMS-C,Hackettclinical score,ChineseAMSscore,
and VAS[C]), AMS is determined by the presence of several neuro-
logical, gastrointestinal, and respiratory symptoms that develop at
high altitude because there is no reliable biomedical test for diag-
nosis of AMS. The number of symptoms evaluated by these instru-
ments varies as does the weighting for the severity of the symp-
toms. The remaining2 instruments (VAS[O] andCFS) exploreother
aspectsofAMS.TheVAS(O)measuresapatient’sperceptionofbeing
unwell fromAMS. The CFS, which has the simplest scoring system,
diagnoses AMS based on the extent of functional impairment of
dailyactivities thatmightoccurathighaltitude.TheLLQScanbecon-
sidered the de facto reference standard for diagnosing AMS for
both clinical and research purposes. Our study showed that even
thoughthevarious instrumentsemphasizedifferentaspectsofAMS,
the VAS(O), AMS-C, and CFS scores performed similarly for diag-
nosing AMS. The performance of the Hackett and Chinese AMS
scores couldnotbeassessedbecauseof insufficientpublisheddata
regarding their diagnostic accuracy.
TherelationshipbetweenaltitudeandAMSwasexaminedusing
random-effectsmeta-regression.Beginningatthealtitudeof2500m
(8200ft), thecommonlyaccepteddefinitionofhighaltitude for ev-
ery 1000 m (3300 ft) of ascent, the prevalence of AMS increased
by approximately 13%. Less than one-third (R2 = 28%) of the rela-
tion between altitude and AMS prevalence was explained by alti-
tudealone.This is likelybecausemanywell-recognizedAMSrisk fac-
tors suchaspreviousepisodes, speedof ascent, preacclimatization,
and use of medical prophylaxis were not controlled for or were
incompletely reported in most studies of AMS.
The AMS-C, the VAS(O), and the CFS had similar diagnostic ac-
curacy for severe AMS when compared with the LLQS when its
score thresholdwas greater than 5. These resultswere not entirely
unexpected for the AMS-C because it was derived from the LLQS.
The similar performance of the VAS(O) and the CFS instruments,
comparedwith theAMS-C,wasnot anticipated.Byassessinganon-
specific functional impairment induced by altitude exposure, inde-
pendentof thepresence andnatureof the symptoms, theCFSand,
in part, theVAS(O) explore different aspects of AMS than the other
instruments.35,58Despite thedifferences inCFSandVAS(O) assess-
ment, theperformanceof these simpler instrumentswas goodand
comparable to thatofAMS-C.Thisobservation is consistentwith the
new concept that AMS might not be a single entity but may mani-
fest indifferentwaysandpresent as symptomclusters that varybe-
tweenpatients (fatigueand insomnia vsheadacheandsleepdistur-
bances vs headache alone).62
Determining which instrument might perform better at diag-
nosing AMS at different altitudes was challenging because the
Table 4. Pooled Diagnostic Accuracy of Selected Instruments for Diagnosis of AcuteMountain Sickness ComparedWith
the Lake Louise Questionnaire Score of 5 or Greater
Source by Instrument
No. of
Participants
Prevalence
of AMS, %
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Positive LR
(95% CI)
Negative LR
(95% CI)
VAS(O)a
Kayser et al,53 2010 80 18 79 (57-100) 92 (86-99) 10 (4.3-25) 0.23 (0.08-0.63)
Van Roo et al,54 2011 45 49 82 (66-98) 91 (80-100) 9.4 (2.5-36) 0.20 (0.08-0.49)
Wagner et al,45 2012b 63 49 65 (48-81) 97 (91-100) 21 (3.0-145) 0.37 (0.23-0.59)
Frühauf et al,46 2016 32 50 50 (26-74) 75 (54-96) 2.0 (0.8-5.3) 0.67 (0.38-0.17)
Summary measuresc 38 69 (55-80) 91 (83-96) 7.6 (3.6-16)
I2 = 64%
0.35 (0.22-0.53)
I2 = 55%
AMS-C ≥0.7
Dellasanta et al,52 2007 266d 43 63 (54-72) 93 (89-97) 9.6 (5.2-18) 0.39 (0.31-0.50)
Wagner et al,45 2012 56e 61 79 (66-93) 82 (66-98) 4.4 (1.8-11) 0.25 (0.13-0.50)
Dehnert et al,55 2014 73 42 77 (63-92) 95 (89-100) 16 (4.1-64) 0.24 (0.12-0.46)
McDevitt et al,22 2014b 3376 28 54 (44-64) 91 (87-95) 6.0 (3.8-9.3) 0.50 (0.40-0.63)
Summary measuresd 37 67 (55-77) 92 (88-95) 8.2 (5.3-13)
I2 = 25%
0.36 (0.26-0.50)
I2 = 62%
CFS ≥2f
Maggiorini et al,47 1998g 490 10 77 (64-89) 93 (91-95) 11 (7.5-16) 0.25 (0.15-0.42)
Dellasanta et al,52 2007 266d 39 82 (74-89) 53 (45-61) 1.7 (1.4-2.1) 0.34 (0.22-0.53)
McDevitt et al,22 2014 337 23 84 (76-93) 55 (49-61) 1.9 (1.6-2.2) 0.28 (0.17-0.48)
Summary measurese 21 82 (77-87) 67 (37-97) 3.2 (1.4-7.2)
I2 = 97%
0.30 (0.22-0.39)
I2 = 0%
Abbreviations: AMS, acute mountain sickness; AMS-C, Acute Mountain
Sickness-Cerebral score; CFS, clinical functional score; LLQS, Lake Louise
Questionnaire Score; LR, likelihood ratio; VAS(O), visual analog scale for the
overall feeling of mountain sickness.
a The thresholds for VAS(O) were heterogeneous between the original studies:
Kayser, 18%;Wagner, 16%; Van Roo, 35%; and Frühauf, 42%.
bAdditional unpublished data were obtained from the authors and used for
calculations.
c Random-effects bivariate meta-analyses were performed for sensitivity,
specificity, and LRs.
d Prevalence analysis was made using the cohort of 266 participants, but
sensitivity and specificity analyses were made using the sample of 1033
LLQS/AMS-C doublets.
e Separate random-effects univariate meta-analyses were performed for
sensitivity, specificity, and LRs.
f CFS is sometimes rated from 1 to 3 rather than 0 to 3, but the clinical definition
of AMS is always the same (symptoms leading to functional impairment) even
if the threshold is sometimes 1 or greater rather than 2 or greater.
g Based on the detailed tables in the study, the sensitivity-specificity 2 × 2 tables
were back-calculated using the LLQS5 as the reference standard for the
purpose of this analysis.
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instruments have not been compared directly with one another at
the same altitudes. At higher altitudes, there is higher risk of AMS
evolving to life-threateninghigh-altitudecerebraledema. In this situ-
ation, an instrumentwithgreater sensitivity (suchas theCFS) ispre-
ferred because it is important to identify cases of AMS even at the
risk of overdiagnosis. At lower altitudes (for example, <4000 m
[13 100ft]),where riskof severeAMS is less,onemight favoramore-
specific instrument such as the AMS-C or VAS(O), which will facili-
tate thedecision for theneedofmedicalprophylaxis if apatientplans
reascent to similar altitude.
In clinical settings, a simple diagnostic instrument such as the
CFS may be adequate, but this may not be true for research stud-
ies. Becausemost research of AMS conducted during the last 2 de-
cades used the LLQS and the AMS-C as reference standards for es-
tablishing a diagnosis of AMS, these 2 instruments remain the best
to use for AMS research because newer studies can then be com-
pared with older ones.
This systematic review highlights the need of a better defini-
tionofAMSbasedoncurrentpathophysiological andclinical under-
standing. An ideal AMS diagnostic instrument should consider the
variableexpressionofAMSsymptomsandavoidconferringtoomuch
weight toasingle symptom.62A longitudinalprospective studywith
repeatedmeasurementsofAMSsymptoms,possiblywithextramea-
surements suchas arterial oxygen saturation,63-65 iswarrantedand
will be required to assess the predictive nature of AMS symptoms.
Limitations
In theabsenceofobjectivemeasures todiagnoseAMS, theLLQSwas
used as a reference standard for establishing a diagnosis of AMS.
The LLQS is not an ideal standard because it relies on the presence
andseverityof thepatient’s subjectivesymptoms.Nostudyhasused
the rapid disappearance of altitude-related symptoms with de-
scent as a reference standard. This approachwould be less depen-
dent on clinical judgment for establishing a diagnosis of AMS.
Because of insufficient granularity of AMS studies for the ex-
aminationof thecontributionof individual symptoms toAMS, itwas
not possible to determine the relative importance of each symp-
tom in each scoring system. This analysis would be important for 2
reasons. First,AMSmightnotbea singleentity.Rather, itmight con-
sist of symptom clusters (fatigue and insomnia vs headache and
sleep disturbances vs headache alone) that affect individuals
differently.62Second,controversyexistsabout the inclusionofhead-
ache as an essential symptom of AMS (required by the LLQS) and
the equivalent weight given to disrupted sleep compared with the
other 4 symptoms (headache, gastrointestinal upset, fatigue, and
dizziness) in the LLQS.66-68
Someof theheterogeneitybetweenstudiesobservedwhenes-
timating the prevalence AMS at different altitudes might be ex-
plained by differences in the individual characteristics of included
participants. The studies of AMS have frequently relied on conve-
nience samples of unselected travelers at different study locations.
Comparedwithstudiesat loweraltitudes (<4000m[13 100ft]), ob-
servational field studies performed at very high altitude might in-
cludemore experienced travelerswhomight be less susceptible to
AMS.At thesehigheraltitudes,generalizationofour findings to trek-
kers and occasional climbers is uncertain.
Thediagnostic instrumentsassessed in this reviewwerenotde-
veloped for usewith children. The languageused in the LLQSques-
tions might require modification for use with children and the in-
strument validated in this population.43,69 Headache, the cardinal
symptomof the LLQS, is difficult to assess in children. Children and
adolescents reportAMSsymptomsat lowaltitude, complicating the
establishment of an AMS diagnosis.43,44 Consequently, we ex-
cluded articles examining AMS in children or adolescents.
Conclusions
For thediagnosis of AMS, theVAS(O), AMS-C, andCFSdisplay simi-
lar performances as the LLQS using a score of 5 or greater, but the
numberof comparisonswas limitedandnot controlled for thepres-
ence of potential risk factors. A pragmatic choice in clinical settings
is to use the CFS because of its simplicity. Travelers with no reduc-
tion or with mild reduction in daily activities should be reassured,
whereas travelerswithmoderateormore reduction in theirdaily ac-
tivities should use the LLQS with a score of 5 or greater in making
the diagnosis of severe AMS requiring intervention.
Scenario Resolution
The clinical vignette depicts a typical presentation of altitude-
related symptoms. Based on our model, predicted prevalence of
moderate tosevereAMSat4000m(13 100ft) isapproximately33%
(Figure). The presence of an important functional impairment
(CFS = 2) frommultiple symptoms in an otherwise healthy person
increases the likelihoodof thatpersonhavingAMS(positiveLR,3.2).
Thus, theprobability that thepatienthasAMS isapproximately55%.
An estimation of the AMS-C can be calculated from the symptoms
listed in the introduction andwould be approximately 1.4, which is
twice the threshold value of 0.7.
The presence of symptoms recorded using the LLQS (fatigue,
dizziness, and nausea) strengthens the likelihood of AMS. This sce-
nario also highlights how a lack of reported headache would have
excluded this diagnosis when using only the LLQS definition be-
cause headache is considered to be a cardinal symptom. This trav-
eler, his companions, orbothneed tounderstand thepotential risks
of AMS (and high-altitude cerebral edema), as well as the impor-
tance of correct behavior and pharmacologic strategies to adopt
when reexposing to similar or higher altitudes.
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